←
Chiara Mercinelli280 posts
Chiara Mercinelli avatar✓

Chiara Mercinelli ✓

@CMercinelli

Genito-Urinary Medical Oncologist at IRCCS San Raffaele Hospital - PhD Candidate in Molecular Medicine at Vita-Salute San Raffaele University

◷ Joined June 2017▧ 31 Photos and videos
Rashid K. Sayyid avatar
⟳ Chiara Mercinelli retweeted
Rashid K. Sayyid@RKSayyid·Oct 25

Bladder preservation after neoadjuvant/perioperative therapy in 🇮🇹 MIBC pts who declined RC and underwent reTURBT (n=54) 📌Negative imaging, biopsy & cytology 🔹19% recurred; 13% developed distant recurrence 🔹 ypT0Nx at reTURBT → 24-mo EFS 88%; MFS & OS >95%, comparable with ypT0N0 after RC 🔹 Residual disease at reTURBT → substantially worse vs non-pCR after RC: 24-mo EFS 19% vs 68%; OS 50% vs 83% 🔹 20% required delayed RC or chemoRT 🔹 Baseline cT3–4 disease also associated with poorer outcomes 🔑 Pathologic clearance at reTURBT may identify a highly selected group for bladder preservation; residual disease was associated with markedly inferior outcomes vs RC. @urotoday #ESMO26

Post attachmentPost attachmentPost attachment
Andrea Necchi, MD, FASCO avatar
⟳ Chiara Mercinelli retweeted
Andrea Necchi, MD, FASCO@AndreaNecchi·Oct 23

This further #ESMO26 @ESMO_Open simultaneous publication is very important for me. @SanRaffaeleMI @MyUniSR Outcomes of pts with MIBC who decline RC in perioperative setting: Take-home message: 1. cCR (Milan criteria) is a reliable biomarker and indicator of outcomes with Systemic Rx and reTURBT 2. Pts who do not get cCR could have a very poor prognosis under bladder-saving approaches > intensification with RC/chemoRT is very much needed Looking forward to ongoing trials (eg EV209, EV309). Congrats to the entire team, also getting Best Poster! @OncoAlert @myESMO @CMercinelli @Anto_cigliola @BrigidaMaiorano @urotoday Piacentini Nasso Serafin et al. Outcomes of patients with muscle-invasive bladder cancer who declined radical cystectomy in perioperative therapy trials conducted at San Raffaele Comprehensive Cancer Center - ESMO Open esmoopen.com/article/S2059-7…

Post attachment
Andrea Necchi, MD, FASCO avatar
⟳ Chiara Mercinelli retweeted
Andrea Necchi, MD, FASCO@AndreaNecchi·Oct 24

With #GDFatherNeo #ESMO26 We brought visugromab+nivo combination neoadjuvantly in pts with MIBC after the initial phase 1 data in refractory setting. 33% CR rates vs 8% Nivo+placebo All pCR pts still event-free (median FUP 15.7m) Only 1 relapse event in major responders in N+V arm (pTa relapse) 4/5 pCR skipped RC in N+V arm. Safety was quite good. Pre-existing CD8+ infiltration associated with N+V Response. It was an illuminating academic-industry collaboration for me. Results simultaneously released today in @NatureMedicine @myESMO @CMercinelli @Anto_cigliola @BrigidaMaiorano @giannatempopatr @DrIacovelli @ciccarese_c and Many more @SanRaffaeleMI @MyUniSR nature.com/articles/s41591-0…